Table 1 Characteristics of the Included Studies and Outcome Events
Study | Countries | Centers | Publication | Type of migraine | Treatment group, (No. of participants) | Total number | Age range | Female (%) | Mean age ± SD (year) | Study period | Outcome Events |
|---|---|---|---|---|---|---|---|---|---|---|---|
Dodick et al. 2014 (NCT01772524) | USA | 26 | Lancet Neurol | episodic | Eptinezumab1000mg (81) vs. PLA (82) | 163 | 18y-55y | Eptinezumab 1000 mg:83 PLA:80 | Eptinezumab 1000 mg:38.6 ± 10.8 PLA:39.0 ± 9.6 | 12 months | a,b,c,d,e,f,g,h |
Dodick et al. 2019 (NCT02275117) | 5 | 92 | Cephalalgia | chronic | Eptinezumab300mg (121) vs.100 mg (122) vs. 30 mg (122) vs.10 mg (130) vs. PLA (121) | 616 | 18y-55y | Eptinezumab 300 mg:81 Eptinezumab 100 mg:85 Eptinezumab 30 mg:91 Eptinezumab 10 mg:87 PLA:90 | Eptinezumab 300 mg:37.2 ± 10.0 Eptinezumab 100 mg:36.7 ± 9.4 Eptinezumab 30 mg:35.7 ± 9.4 Eptinezumab 10 mg:36.4 ± 10.3 PLA:37.2 ± 9.2 | 24 months | a,b,c,d,f,g,h,j |
Ashina et al. 2020 (NCT02559895) | 2 | 84 | Cephalalgia | episodic | Eptinezumab300mg (224) vs.100 mg (223) vs.30 mg (219) vs. PLA (222) | 888 | 18y-75y | Eptinezumab 300 mg:89 Eptinezumab 100 mg:80 Eptinezumab 30 mg:84 PLA:84 | Eptinezumab 300 mg:40.2 ± 11.72 Eptinezumab 100 mg:40.0 ± 10.66 Eptinezumab 30 mg:39.1 ± 11.54 PLA:39.9 ± 11.67 | 26 months | a,b,c,d,g,j |
Lipton et al. 2020 (NCT02974153) | 13 | 128 | Neurology | chronic | Eptinezumab300mg (350) vs.100 mg (356) vs. PLA (366) | 1072 | 18y-65y | Eptinezumab 300 mg:90 Eptinezumab 100 mg:86 PLA:89 | Eptinezumab 300 mg:41.0 ± 10.4 Eptinezumab 100 mg:41.0 ± 11.7 PLA:39.6 ± 11.3 | 18 months | a,b,c,d,f,g,j |